Rheumatoid Arthritis Treatment Doesn't Promote Cancer

No added risk among patients taking immunosuppressants, research shows

Related Encyclopedia • Adenocarcinoma of the Lung and Brain Metastases • Alzheimer's Disease • Arthritis • Arthroscopy & Arthroscopic Surgery More... Related Healthscout Videos Shutting Down Tremor. What's Your Stroke IQ? Disaster Heart Attacks Teaching Old Docs New Tricks More... Related Animations • Alzheimer's Disease Video Animation • Breast Self-Exam Video • Colon Cancer • Erectile Dysfunction More... Related Drug Information • Actonel • Coumadin • Detrol LA • Ditropan XL More... Related News Articles • Deadly Stomach Bug Making Inroads Outside Hospitals • Sugar Shortens Life Span in Worms • Switch to 'Light' Cigarettes Makes Quitting Tougher • CDC Finds U.S. 30th in Infant Mortality More...

THURSDAY, Oct. 29 (HealthDay News) -- Treatment with tumor necrosis factor (TNF) blockers doesn't increase rheumatoid arthritis patients' risk of cancer, new research has found.

TNF is a substance secreted by immune cells that regulates the immune system and plays a role in inflammation. TNF blockers are immunosuppressants that reduce inflammation in people with rheumatoid arthritis, but concerns have been raised that long-term use of the drugs may increase the risk of infections and cancer.

Text Continues Below

---

Swedish researchers analyzed data from 6,366 rheumatoid arthritis patients who started anti-TNF therapy with infliximab (Remicade), adalimumab (Humira) or etanercept (Enbrel) between January 1999 and July 2006. The study participants were compared with other groups of rheumatoid arthritis patients, including 61,160 not taking medications, 4,015 taking methotrexate (the gold standard of treatment) and 4,105 taking combinations of disease-modifying anti-rheumatic drugs (other than TNF blockers).

According to the study authors, 240 first cancers were diagnosed during follow-up among patients who had no history of cancer when they began anti-TNF treatment. Compared to rheumatoid arthritis patients who didn't take anti-TNF drugs or those with no history of cancer, the relative cancer risk of anti-TNF therapy was 1.00 and remained unchanged for those taking immunosuppressant drugs for up to six years, the researchers found.

"Our research indicates the overall cancer risk is the same for rheumatoid arthritis patients on immunosuppressant therapies and those not taking medications for the disease," confirmed team leader Dr. Johan Askling, of the Karolinska University Hospital in Stockholm, in a news release. However, "given several uncertainties, continued vigilance remains prudent."

The study is published in the November issue of Arthritis & Rheumatism.

More information

The American Academy of Family Physicians has more about rheumatoid arthritis.

-- Robert Preidt